Hydroxychloroquine has been prescribed for more than seventy years, first as an antimalarial and later as one of the most reliable long-term treatments for lupus and rheumatoid arthritis. It also became, briefly and controversially, one of the most talked-about drugs in the world during the early COVID-19 pandemic. This article separates what is well established from what was hoped for but not confirmed, and answers the practical questions patients and families actually ask their pharmacist or physician.

What hydroxychloroquine is, and what it is not

Hydroxychloroquine is a synthetic derivative of quinine, the compound isolated from the bark of the cinchona tree, which people native to South America and later European physicians used for centuries to treat fevers. It is worth pausing on that: a genuinely useful modern medicine traces its lineage to a tree bark remedy, a reminder that the natural world has long held resources that careful observation and chemistry eventually refined into something more precise and consistent.

It is not an antibiotic. It has no activity against bacteria and is never used to treat bacterial infections. It is not a steroid either, though it is often prescribed alongside steroids like prednisone in autoimmune disease, which is likely where the confusion arises. Pharmacologically it is classed as an antimalarial and, in its use for lupus and rheumatoid arthritis, as a disease-modifying antirheumatic drug (DMARD). It works by interfering with immune cell signaling and altering the acidity inside certain cellular compartments, which dampens the overactive immune activity seen in autoimmune disease and disrupts the malaria parasite's ability to process hemoglobin.

It is not addictive. It has no effect on dopamine reward pathways, no withdrawal syndrome, and is not a controlled substance. And yes, in every country with a functioning regulatory system, it requires a prescription. It is not available over the counter, both because incorrect dosing carries real cardiac risk and because ongoing monitoring, discussed below, is part of using it safely.

Approved uses, and how well it actually works for them

Hydroxychloroquine is approved for treating and preventing malaria, and for treating systemic lupus erythematosus, discoid lupus, and rheumatoid arthritis. For these conditions the evidence is not preliminary or contested; it is decades deep, drawn from randomized controlled trials and long-term cohort studies, and it forms the backbone of standard rheumatology treatment guidelines worldwide.

For lupus specifically, hydroxychloroquine is considered close to indispensable. Long-term observational studies, including work published in journals such as Arthritis & Rheumatology, have associated consistent hydroxychloroquine use with fewer disease flares, reduced organ damage over time, and even a survival benefit in some cohorts. For rheumatoid arthritis it is milder than other DMARDs and is often used in combination with other agents rather than alone in more aggressive disease.

So does it work? For its approved indications, yes, with strong and repeated evidence behind it. What it does not do is act quickly. Patients sometimes expect an antibiotic-like response within days. That is not how it behaves in autoimmune disease. Most patients need four to twelve weeks before they notice meaningful improvement in joint pain, fatigue, or skin symptoms, and the fullest benefit may take three to six months to appear. The first signs people typically notice are subtle: slightly less morning stiffness, a day or two fewer of joint swelling, mild skin rashes fading. There is no dramatic single moment where you know it is "working" the way a fever breaking tells you an antibiotic is working. Malaria treatment is different: because the drug is acting directly against a parasite in the bloodstream rather than recalibrating a slow-moving immune process, improvement in acute malaria symptoms can be seen within a few days.

Taking it correctly: food, timing, and daily use

Hydroxychloroquine is usually taken with food or milk, not on an empty stomach. This is worth correcting directly, because the opposite idea circulates: nausea and stomach cramping are among its most common side effects, and taking it with a meal reliably reduces this. There is no clinical reason to take it on an empty stomach, and doing so tends to make tolerability worse, not better.

For lupus and rheumatoid arthritis, it is taken every day, typically once or, for higher total doses, split into two doses, and it is intended for sustained, regular use rather than as-needed dosing. Missing occasional doses will not cause acute harm, but consistent daily use is what produces the slow accumulation of benefit described above. There is no particular advantage to morning versus evening dosing; the deciding factor is usually whichever time makes it easiest for the individual patient to remember and pair with a meal. Some patients find taking it with their largest meal, whenever that falls, minimizes stomach upset most effectively.

For malaria prevention, dosing follows a distinct weekly schedule starting before travel and continuing after return, prescribed according to destination and current resistance patterns; this is a different regimen entirely from the daily dosing used in autoimmune disease and should be set up directly with a travel medicine provider.

Can it be taken long term? Yes, and for lupus and rheumatoid arthritis this is the norm rather than the exception; many patients remain on it for years or decades. Long-term use is precisely why monitoring matters, discussed next.

Monitoring, side effects, and what to avoid

The most serious long-term risk is a rare but real form of retinal toxicity. Hydroxychloroquine can accumulate in the retina over years of use, and in a small percentage of long-term users this leads to progressive, irreversible vision damage if unmonitored. The American Academy of Ophthalmology recommends a baseline eye exam when starting the drug and annual screening beginning after five years of use, sooner if a patient is on a higher dose relative to body weight, has kidney disease, or takes tamoxifen alongside it. This is not a reason for alarm; it is a reason for the kind of disciplined follow-through that makes long-term use safe. Skipping the eye exams is the actual risk, not the drug itself when properly monitored.

More common but less serious effects include nausea, diarrhea, headache, and mild fatigue. Yes, hydroxychloroquine can make some people feel tired, particularly when starting treatment; this often eases after the first few weeks. Skin pigmentation changes and, rarely, muscle weakness can occur with prolonged use. Cardiac effects are uncommon at standard doses but become relevant when hydroxychloroquine is combined with other drugs that prolong the heart's QT interval, which is why physicians review a patient's full medication list before prescribing it.

What should you avoid while taking it? The clearest guidance:

Alcohol does not have a dangerous, direct interaction with hydroxychloroquine the way it does with some medications, but moderate-to-heavy drinking increases the burden on the liver and can worsen nausea and dizziness, and lupus and rheumatoid arthritis patients are frequently on other medications, such as methotrexate, where alcohol matters a great deal. The sensible course is to discuss your actual drinking habits honestly with your prescriber rather than assume a blanket answer applies to your case.

Overdose is a genuine medical emergency and one of the reasons this drug is prescription-only. Because the margin between a therapeutic dose and a dangerous one is narrower than with many common medications, an overdose, even one that might seem modest in tablet count, can cause severe low blood pressure, dangerous heart rhythm disturbances, low potassium, and seizures, and has been fatal in reported cases. Anyone who takes more than their prescribed dose, or who ingests a child's accidental exposure, needs immediate emergency evaluation, not a wait-and-see approach.

The COVID-19 question, answered plainly

Early in 2020, small non-randomized studies, including one from a research group in Marseille, France, and separate laboratory work showing antiviral activity against the virus in cell culture, generated real hope that hydroxychloroquine might help treat or prevent COVID-19. That hope was reasonable to investigate and was investigated seriously and quickly.

The subsequent evidence did not support it. The RECOVERY trial, a large randomized controlled trial run by the University of Oxford involving thousands of hospitalized COVID-19 patients, found no reduction in mortality among those given hydroxychloroquine, and that arm of the trial was stopped in mid-2020. The World Health Organization's Solidarity trial, conducted across many countries, reached the same conclusion. On the strength of this evidence, the U.S. Food and Drug Administration revoked its emergency authorization for hydroxychloroquine in COVID-19 in June 2020, and it is not approved for COVID-19 treatment or prevention today.

This is a useful case study in how medicine actually works: a plausible mechanism and encouraging small studies pointed one direction, larger and better-controlled human trials pointed another, and the larger trials, being more rigorous, carried the day. That is the system functioning as it should, not evidence of anything being hidden. Patients considering it for an unapproved use should understand plainly that the best available human trial data found no benefit, and should raise the question directly with their own physician rather than rely on outdated news coverage.

Talking with your doctor

Hydroxychloroquine remains a genuinely valuable, well-understood medicine for the conditions it is approved to treat, including for women managing lupus through pregnancy, where it is generally considered one of the safer options for controlling maternal disease while protecting the child. Its value comes precisely from decades of careful human study, not from novelty. The right approach with any long-term medication is the same one that respects both the patient and the evidence: understand what it treats, take it as directed, keep your monitoring appointments, and raise concerns directly with the physician who knows your history rather than relying on general advice, including this article, as a substitute for that relationship.

Key takeaway: Hydroxychloroquine is a well-proven, slow-acting therapy for malaria, lupus, and rheumatoid arthritis that requires patience, consistent daily use with food, and regular monitoring, but the strongest human trial evidence has found no benefit for COVID-19.